MYNZ - Mainz Biomed N.V. 0 WATCHERS

Why Germany First Matters For A Rerate After The DoctorBox Integration Germany is one of Europe’s largest CRC markets, with about 60,000 new cases a year. Dropping ColoAlert into DoctorBox’s preventive platform puts MYNZ in front of 1,000,000+ users with 10M+ results already delivered and baked-in reminders that nudge people …

DoctorBox Uptake Math: What Would “Real” Look Like In 90 Days DoctorBox lists 1,000,000+ users and 10M+ results. If 1 percent initiated a ColoAlert order in 12 months, that is 10,000 kits. If half of those complete, you are looking at 5,000 completed tests. This is illustrative math, not guidance, …

Digital Integration Is The New Sales Rep: Screening From Reminder To Result DoctorBox does what sales reps cannot. It nudges users with guideline reminders, captures orders at home, routes samples, and delivers results with next steps in one workflow. That reduces friction and can lift adherence. Germany sees roughly 60,000 …

DoctorBox Adds ColoAlert: Real Distribution Inside A 1M User Preventive Platform DoctorBox just added ColoAlert to its portfolio. That is not a vanity partnership. DoctorBox has 1,000,000+ registered users and has processed 10M+ test results, with built-in reminders that nudge people to screen at home. Germany sees roughly 60,000 colorectal …

Europe’s Preventive Funnel Opens For ColoAlert; Three Names Worth A Look The DoctorBox integration puts ColoAlert in front of a large, engaged audience. With 1,000,000+ users and 10M+ results delivered, DoctorBox already guides preventive care with age and risk-based reminders. That can translate to organic demand for MYNZ, which reports …

Mynz Dropped news 20 min ago: [https://www.stocktitan.net/news/MYNZ/doctor-box-adds-mainz-biomed-s-colo-alert-r-to-its-d1ftgnskm3k3.html](https://www.stocktitan.net/news/MYNZ/doctor-box-adds-mainz-biomed-s-colo-alert-r-to-its-d1ftgnskm3k3.html)

Conferences Are Not Just Photos. They Fill Pipelines If Follow-Ups Land Quiet tapes make conference follow-ups more important than headlines. MEDICA brings roughly 80,000 attendees and 5,000 plus exhibitors. Regional meetings like GARPS put sellers in front of practicing GI clinicians. For MYNZ, the scoreboard is simple: qualified meetings logged, …

Fed Week Noise Is High; Trade The Calendar You Can Verify Across Names Index timing is messy into rate headlines. I prefer dated catalysts. MYNZ has a feasibility read targeted for 2025 to lock a final CRC panel, then a 2026 pivotal around 15,000 patients and about 150 U.S. sites …

AI Debt Jitters In Tech; In Diagnostics, Let The Data And Delivery Do The Talking AI heavy names are under scrutiny today, so I am focusing on diagnostics with measurable results. MYNZ reports pooled next gen CRC data near 92% sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia, plus pancreas …

Gold Up, Vol Jumpy. Prevention Economics Still Make Sense Safe havens are firmer and volatility is elevated. That does not change the math on screening. Colorectal cancer hits roughly 1.9 million people each year and causes about 935,000 deaths. Five year survival is near 90% when localized and drops to …

You didn't even mention the stock, MYNZ 🤣 it will be a meme stock until FDA labs, full stop.

Lets see about that. [MYNZ](http://aimytrade.io/ticker/MYNZ)

Reimbursement is the unlock. Performance buys coverage Diagnostics do not scale without coverage. The math is harsh. Patients screen when payers pay. For CRC, the addressable pool is huge but adherence lags near 60 to 65 percent in the U.S. A test that pairs high sensitivity with patient friendly collection …

CRC screening is a massive market with a compliance gap you can drive a truck through Colorectal cancer is not niche. Globally it accounts for roughly 1.9 million new cases a year. In the U.S., it is about 150k new cases and around 50k deaths annually. Screening works, yet real-world …

A Small Country Is Proving the Roadmap for a Big Cancer Screen Forget the US headlines for a minute. The real story to watch right now for Mainz Biomed (MYNZ) is happening in Europe, and it all starts with Switzerland. Why is this important? * It's the first real test …

Big Pharma Just Got Behind a Tiny Cancer Test Company I saw some news today that might be flying under the radar, but it's a huge deal for execution risk in the diagnostics world. The company is Mainz Biomed (MYNZ), and they've just announced a major collaboration with Thermo Fisher. …

Revenue trend is finally pointing the right way You do not have to worship a story to notice when the numbers stop fighting it. In 2024, MYNZ’s lab-network revenue grew about 33 percent year over year. Operating loss fell roughly 30 percent. Net loss improved about 18 percent. That is …

Thermo Fisher is the difference between a pitch and a product Mainz Biomed is not doing the "new logo, new story" shuffle. They signed a real collaboration with Thermo Fisher on the next-gen colorectal cancer test. That matters for three reasons. First, manufacturing discipline. You do not scale diagnostics with …

Europe is opening and Switzerland is the wedge ColoAlert picked up Swissmedic approval and a lab partner for Switzerland. That is not a press-release trophy. It is a go-to-market wedge in a country with high screening awareness and strong lab infrastructure. Europe is the right way to build the base …

Mainz Biomed (MYNZ): credible turnaround, real partners, and a cleaner path than the usual penny circus MYNZ finished at 1.12 on Nov 26, up about 13 percent on modest volume. It is still a microcap, but it is not the kind of “tennis balls yesterday, AI today” shell game you …

Mainz Biomed (MYNZ): real progress, real risks, worth a second look MYNZ closed at 1.12 on Nov 26, up about 13 percent on light volume. The chart still looks bruised, but the operating story is cleaner than it was a year ago. # What actually changed * Revenue from the …

Major European Push Underway for a Life-Saving Test! There's been a lot of talk lately about a small diagnostics company making big moves in Europe, and it looks like the chatter is for real. Why does this matter? Because we're talking about screening for Colorectal Cancer (CRC), a major problem …

MCED And AI Are Lifting The Whole Early Detection Trade Headlines around multi cancer blood tests and AI screening are everywhere. That helps targeted screens too, because payers and hospitals are already debating coverage, workflow, and economics. In that context, MYNZ sits as a focused CRC and pancreas platform rather …

Top 5 Event Calendar To Watch Over The Next Two Quarters SEQUA: U.S. commercialization for its medical pump is starting to show up in chatter. Near-term checks are first purchase orders, hospital onboarding pace, and gross margin in the next report. If reorders appear, the story upgrades. MYNZ: diagnostics name …

Top 3 Picks Fundamentals First: Real Ops And Data MYNZ has an operating wedge. It sells a CRC screen in Europe through partner labs and has pooled study metrics that matter to clinicians. CRC sensitivity about 92 percent, advanced adenomas 82 percent, and high grade dysplasia 95.8 percent. The U.S. …

A Simple Valuation Framework: What Would Close The Gap For A Microcap Screen You do not need a price target to build a view. Start with drivers that move a diagnostics multiple. Clinical proof at scale: MYNZ plans a pivotal around 15,000 patients across about 150 U.S. sites after a …

Europe’s 90 Percent Screening Goal: Why Policy Is A Tailwind For A Small Player The EU’s Beating Cancer Plan targets 90% CRC screening coverage in eligible citizens. That is a policy push, not a headline. It means systems are expected to expand programs and close gaps between countries. CRC remains …

Thermo Fisher + Kits: The Simple Path To Scale For A Tiny Diagnostics Name Thermo Fisher’s role here is not window dressing. The collaboration is about turning ColoAlert into a kitted assay that runs on widely deployed platforms, so any qualified lab can plug it in. That supports a decentralized …

Pivotal At Real Scale: 15,000 Patients Across 150 Sites Can Change The Math ReconAAsense is not a pilot. The planned pivotal for MYNZ targets about 15,000 patients across roughly 150 U.S. sites, following an FDA pre-submission in 2022 and early CMS discussions. That kind of scale is what regulators and …

Post-Abbott-Exact World: What A $23B CRC Deal Implies For Small Screens Abbott just agreed to acquire Exact Sciences for about $105 per share, roughly $21B equity value and about $23B including debt. That is a sector reset for colorectal screening platforms like Cologuard and Oncotype under one roof. It tells …

The U.S. Corridor Is Open: FDA And Medicare Already Pay For Noninvasive CRC This is no longer a what-if market. Shield, Guardant’s blood test, is FDA approved as a primary CRC screen for average-risk adults and meets Medicare coverage requirements. Exact’s next-gen Cologuard Plus is FDA approved and slated to …

IXHL MYNZ

Clouds, Colon, Courage: Manual About Catching Trouble Early In this satire, a city wakes to streaks across the sky and a thousand low effort conspiracy threads. Meanwhile the real work happens in clinics. People breathe, swallow, and in our fictional setup a tiny fraction of those sky particles reach the …

The Great Chemtrail Cleanout: A Fake Public Health Plan That Actually Makes Sense Imagine this purely fictional policy memo. Step one, stop yelling at clouds. Step two, screen people before the pretend particles do harm. Early detection beats late treatment on outcomes and cost. Localized colorectal cancer often gets handled …

Swissmedic Approval Secured: How Switzerland Can Prove The Model Works Switzerland cleared ColoAlert on August 13, 2025, and the test will be offered through local partner labor team w ag. That removes regulatory friction. What matters now is execution. Track the number of Swiss ordering sites, average turnaround times as …

Why A Partner-Lab Model Can Expand Fast: Margin Logic And Execution KPIs Instead of building a single mega lab, MYNZ sells ColoAlert as a kit and lets partner labs run it. That model is already live in Europe and newly cleared in the UK (registration Sept 2, 2025) and Switzerland …

Thermo Fisher’s Role: From Prototype To Plug-And-Play Kits That Any Lab Can Run MYNZ is aligning with Thermo Fisher Scientific to develop a next-generation, kitted version of ColoAlert that can run on widely deployed platforms. That shift matters for scale. A decentralized kit lowers capital needs, speeds validation across multiple …

The Scale Partner Most Traders Miss: Why A Quest Option Changes The US Math Quest Diagnostics DGX is not just a logo on a slide. Under the December 2024 agreement, Quest provides central lab services for MYNZ’s pivotal ReconAAsense trial and, if FDA approves, holds an 18-month semi-exclusive option to …

ReconAAsense At Scale: ~15,000 Patients, ~150 U.S. Sites, Built For FDA And Payers The pivotal design is not a small pilot. ReconAAsense targets about 15,000 patients across roughly 150 U.S. sites. Scale like that is what FDA reviewers and payers expect for a nationwide screening claim. The company completed an …

Single-Asset Reality Check: When Most Future Revenue Rests On One Test The company is upfront about it. Almost all future revenue depends on ColoAlert, per filings. That makes MYNZ a classic single-asset bet. If ReconAAsense hits, FDA approves, and adoption follows, the upside can be real. If the pivotal stumbles …

ColoAlert In Plain English: How A PCR Stool DNA Test Competes In CRC Screening Here is what МYNZ actually sells. ColoAlert is a PCR-based multiplex stool DNA assay aimed at early colorectal cancer detection. It looks for molecular biomarkers in stool and is non invasive. Think of it as the …

Price The Risks Like A Pro: Dilution, Timing, Competition Microcap diagnostics is not free. MYNZ reported limited cash around mid 2025, used roughly multi million operating cash per half year, and has an at the market program active. Float is about 5.2 million shares. That mix means offering risk is …

How An Asset-Light Model Can Scale Screening In 2026 The operating thesis is simple. Let partner labs run the assay, keep capital light, and focus in house on onboarding, training, logistics, and reorders. That is how MYNZ approaches ColoAlert, which the company reports at about 97% sensitivity, 97% specificity, and …

Top 3 Small Caps Showing Real Momentum Potential Before Major Catalysts Small cap biotech is moving again as traders rotate into names with visible events and clear risk lines. These three keep showing up because each has a catalyst window that the market cannot ignore. MIST A December PDUFA on …

Top 3 Small Cap Biotech Setups With Real Near Term Movement Potential ACHV Cytisinicline’s accepted NDA and a June 2026 decision date give this one a clear regulatory arc instead of guessing Games. The market is waiting to see if they announce a commercial partner before year end since that …

Top 5 Pre-And Post-FDA Biotechs Under 6 With Clear Timelines If you want binary-style catalysts but still under 6 dollars, these five names at least have visible timelines and not just vague “pipeline” talk. * **NASDAQ: ACHV** around 3.9 has cytisinicline with an accepted NDA and a June 20, 2026 …

MYNZ What are everyone's thoughts on MYNZ? Their earnings are released tonight after the market closes. Additionally, Mainz Biomed and Oncovanguard8 Enter into an Agreement to Bring Coloalert to South America. Could we potentially see a small push? They are a molecular genetics cancer diagnostic company. The firm is engaged …

Mainz Biomed ($MYNZ) What are everyone's thoughts on MYNZ? Their earnings are released tonight after the market closes. Additionally, Mainz Biomed and Oncovanguard8 Enter into an Agreement to Bring Coloalert to South America. Could we potentially see a small push? They are a molecular genetics cancer diagnostic company. The firm …

What’s the play for tmr??? I’m holding VIVK, and MYNZ, and going to buy more TRUG and DVLT

TRUG and VIVK for sure. Maybe watch MYNZ

MYNZ and TRUG We are breaking the resistance for both right now, buy in before its too late!!